AGI AGI

 

TIDMAGI 
 
RNS Number : 8723D 
AGI Therapeutics plc 
10 December 2009 
 
 
 
 
 
 
 
AGI Therapeutics Plc 
("the Company") 
 
 
Appointment of Nominated Adviser 
 
 
 
 
AGI Therapeutics Plc (AIM, IEX: AGI), a speciality pharmaceutical development 
company announces  that  Davy has been appointed as the Company's Nominated 
Adviser with immediate effect. 
 
 
 
 
 
 
Contact Information: 
 
 
AGI Therapeutics plc. 
 Tel: +353 1 449 3254 
David Kelly, Chief Financial Officer 
 
 
Davy 
John Frain 
 Tel: +353 1 679 6363 
 
For further information please see www.agitherapeutics.com. 
 
 
 
 
 
 
Notes to Editors: 
 
 
 
 
About AGI Therapeutics plc 
 
 
AGI is a specialty pharmaceutical company which is focused on the development 
and commercialisation of differentiated specialty drug products to treat unmet 
medical needs, including conditions which qualify for Orphan drug status. 
 
 
The company has a portfolio of product candidates derived from its Known 
Molecular Entity (KME(TM)) approach to drug re-profiling and development and 
aims to bring its products to the market either directly or through 
out-licensing or other partnering arrangements. 
 
 
AGI's common shares are listed on the Alternative Investment Market of the 
London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish 
Stock Market (IEX) as AGI. 
 
 
 
 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 APPDGMGZVLKGLZM 
 

AGI (LSE:AGI)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025

AGI (LSE:AGI)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025